Other Events ·
FDA authorizes Gain Therapeutics' IND for GT-02287 to begin Phase 2 Parkinson's trials
GANXGain Therapeutics, Inc.
Gain Therapeutics, Inc. announced on June 29, 2026, that the U.S. Food and Drug Administration (FDA) authorized its Investigational New Drug application for GT-02287. This authorization allows the company to initiate Phase 2 clinical development of GT-02287 for Parkinson's disease in the United States, Australia, and Europe. The company anticipates the initiation of the Phase 2a study of oral GT-02287 in participants with early Parkinson's disease during the third quarter of 2026. Gain Therapeutics, Inc. is a biotechnology company focused on the development of therapeutic candidates for neurological and neurological-related diseases.